These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38626241)

  • 21. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints.
    Turnidge JD;
    Clin Infect Dis; 2011 Apr; 52(7):917-24. PubMed ID: 21427400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).
    Simpson I; Durodie J; Knott S; Shea B; Wilson J; Machka K
    J Clin Microbiol; 1998 May; 36(5):1361-5. PubMed ID: 9574706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Greece.
    Torumkuney D; Papaparaskevas J; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v36-v42. PubMed ID: 29659884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigation of Plasmid Mediated mcr Colistin Resistance Gene in Clinical Enterobacterales Isolates].
    Özkaya E; Buruk CK; Tosun İ; Toraman B; Kaklıkkaya N; Aydın F
    Mikrobiyol Bul; 2020 Apr; 54(2):191-202. PubMed ID: 32723275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.
    Pierce VM; Mathers AJ
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):73-80. PubMed ID: 34888640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.
    Satlin MJ; Nicolau DP; Humphries RM; Kuti JL; Campeau SA; Lewis Ii JS; Weinstein MP; Jorgensen JH
    Clin Infect Dis; 2020 Mar; 70(6):1240-1246. PubMed ID: 31504338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?
    Tamma PD; Wu H; Gerber JS; Hsu AJ; Tekle T; Carroll KC; Cosgrove SE
    Pediatr Infect Dis J; 2013 Sep; 32(9):965-9. PubMed ID: 23470679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic
    Ract P; Compain F; Robin F; Decre D; Gallah S; Podglajen I
    J Med Microbiol; 2019 Sep; 68(9):1292-1298. PubMed ID: 31361213
    [No Abstract]   [Full Text] [Related]  

  • 30. Overview of Changes to the Clinical and Laboratory Standards Institute
    Humphries R; Bobenchik AM; Hindler JA; Schuetz AN
    J Clin Microbiol; 2021 Nov; 59(12):e0021321. PubMed ID: 34550809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
    MacGowan A
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Haemophilus influenzae EUCAST and CLSI disc diffusion methods to recognize aminopenicillin and amoxicillin/clavulanate resistance.
    Fernando SA; Pang S; McKew GL; Phan T; Merlino J; Coombs GW; Gottlieb T
    J Antimicrob Chemother; 2020 Sep; 75(9):2594-2598. PubMed ID: 32585694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amoxicillin/clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute.
    Narayanan N; Mathers AJ; Wenzler E; Moore NM; Giske CG; Mendes RE; Edelstein PH
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38709848
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
    Dudley MN; Ambrose PG; Bhavnani SM; Craig WA; Ferraro MJ; Jones RN;
    Clin Infect Dis; 2013 May; 56(9):1301-9. PubMed ID: 23334813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of in vitro susceptibility testing results for amoxicillin-clavulanate and ampicillin-sulbactam using a panel of beta-lactamase-producing Enterobacteriaceae.
    Siu LK; Cheng WL; Ho PL; Ng WS; Chau PY; Lo JY
    APMIS; 1998 Sep; 106(9):917-20. PubMed ID: 9808419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility.
    Aggarwal P; Saxena S; Nagi N
    Indian J Med Microbiol; 2024; 49():100602. PubMed ID: 38697481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.